|
US5545644A
(en)
|
1990-10-15 |
1996-08-13 |
Pfizer Inc. |
Indole derivatives
|
|
US5559129A
(en)
|
1990-10-15 |
1996-09-24 |
Pfizer Inc |
Indole derivatives
|
|
US5607951A
(en)
|
1990-10-15 |
1997-03-04 |
Pfizer Inc |
Indole derivatives
|
|
US5120749A
(en)
|
1991-02-20 |
1992-06-09 |
Abbott Laboratories |
Platelet activating antagonists
|
|
TW288010B
(https=)
*
|
1992-03-05 |
1996-10-11 |
Pfizer |
|
|
SK280193B6
(sk)
*
|
1992-04-07 |
1999-09-10 |
Pfizer Inc. |
Indolové deriváty predstavujúce 5-ht1 agonisty, fa
|
|
ATE144773T1
(de)
*
|
1993-04-22 |
1996-11-15 |
Pfizer Res & Dev |
Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
|
|
AP486A
(en)
*
|
1993-04-27 |
1996-04-16 |
Pfizer |
Indole derivatives.
|
|
FR2735774B1
(fr)
|
1995-06-21 |
1997-09-12 |
Sanofi Sa |
Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
|
|
US5955462A
(en)
|
1996-10-31 |
1999-09-21 |
Harbor Branch Oceanographic Institution, Inc. |
Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
|
|
US6100291A
(en)
|
1998-03-16 |
2000-08-08 |
Allelix Biopharmaceuticals Inc. |
Pyrrolidine-indole compounds having 5-HT6 affinity
|
|
GB9816263D0
(en)
|
1998-07-24 |
1998-09-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US6218423B1
(en)
|
1998-08-14 |
2001-04-17 |
Gpi Nil Holdings, Inc. |
Pyrrolidine derivatives for vision and memory disorders
|
|
GB9923314D0
(en)
|
1999-10-01 |
1999-12-08 |
Pfizer Ltd |
Acylation process
|
|
WO2001094310A1
(en)
|
2000-06-07 |
2001-12-13 |
The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Methods for making bis-heterocyclic alkaloids
|
|
US7135479B2
(en)
|
2002-09-12 |
2006-11-14 |
Wyeth |
Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
|
|
WO2004106298A1
(en)
|
2003-05-30 |
2004-12-09 |
Janssen Pharmaceutica N.V. |
Indole derivatives with an improved antipsychotic activity
|
|
US7700612B2
(en)
*
|
2003-12-23 |
2010-04-20 |
Abraxis Bioscience, Llc |
Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
|
|
ATE474833T1
(de)
|
2004-09-22 |
2010-08-15 |
Janssen Pharmaceutica Nv |
Inhibitoren der wechselwirkung zwischen mdm2 und p53
|
|
ES2357129T3
(es)
|
2005-04-13 |
2011-04-19 |
Neuraxon Inc. |
Compuestos indólicos sustituidos que tienen actividad inhibidora de nos.
|
|
US8003624B2
(en)
|
2005-08-25 |
2011-08-23 |
Schering Corporation |
Functionally selective ALPHA2C adrenoreceptor agonists
|
|
JP5137849B2
(ja)
|
2006-01-19 |
2013-02-06 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
|
|
US20090306137A1
(en)
*
|
2006-05-22 |
2009-12-10 |
Wolfgang Curt D |
Treatment for depressive disorders
|
|
US7964728B2
(en)
|
2006-07-06 |
2011-06-21 |
Solvay Pharmaceuticals B.V. |
Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
|
|
WO2008036967A2
(en)
|
2006-09-22 |
2008-03-27 |
Reddy Us Therapeutics, Inc. |
Novel heterocyclic compounds as lasy activators
|
|
US20090014868A1
(en)
|
2007-07-10 |
2009-01-15 |
International Business Machines Corporation |
Manufacturing ic chip in portions for later combining, and related structure
|
|
KR20100103799A
(ko)
|
2007-11-16 |
2010-09-28 |
네우렉슨 인코포레이티드 |
내장통을 치료하기 위한 인돌 화합물 및 방법
|
|
US20100022581A1
(en)
|
2008-07-02 |
2010-01-28 |
Memory Pharmaceuticals Corporation |
Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
|
|
WO2010132072A1
(en)
|
2009-05-15 |
2010-11-18 |
Neuraxon, Inc |
Treatment or prevention of migraine by dosing at aura
|
|
JP5959537B2
(ja)
|
2011-01-28 |
2016-08-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
置換ピリジニル−ピリミジン及び医薬としてのその使用
|
|
PT3160464T
(pt)
*
|
2014-06-26 |
2018-10-12 |
Contera Pharma Aps |
6-hidroxibuspirona para uso no tratamento de transtornos do movimento
|
|
GB201511382D0
(en)
|
2015-06-29 |
2015-08-12 |
Imp Innovations Ltd |
Novel compounds and their use in therapy
|
|
MA42769B1
(fr)
*
|
2015-09-10 |
2019-12-31 |
Suven Life Sciences Ltd |
Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
|
|
WO2018064465A1
(en)
|
2016-09-29 |
2018-04-05 |
The Regents Of The University Of California |
Compounds for increasing neural plasticity
|
|
US20190358238A1
(en)
|
2016-11-16 |
2019-11-28 |
University Of South Florida |
ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
|
|
CA3077053A1
(en)
*
|
2017-09-27 |
2019-04-04 |
Ohio State Innovation Foundation |
Methods and compositions for inhibition of stat3
|
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
AU2020215150B8
(en)
|
2019-01-30 |
2025-07-03 |
Diamond Therapeutics Inc. |
Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
|
|
EP4219498A1
(en)
|
2019-03-07 |
2023-08-02 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
|
|
GB201907871D0
(en)
|
2019-06-03 |
2019-07-17 |
Small Pharma Ltd |
Therapeutic compositions
|
|
CA3160793A1
(en)
|
2019-12-04 |
2021-06-10 |
Neonmind Biosciences Inc. |
Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
|
|
MX2022009528A
(es)
*
|
2020-02-04 |
2022-11-14 |
Mindset Pharma Inc |
Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
|
|
JP2023514559A
(ja)
|
2020-02-05 |
2023-04-06 |
イエール ユニバーシティ |
頭痛障害の幻覚剤処置
|
|
KR20240096817A
(ko)
|
2020-05-19 |
2024-06-26 |
사이빈 아이알엘 리미티드 |
중수소화된 트립타민 유도체 및 사용 방법
|
|
EP3902541B1
(en)
|
2020-06-02 |
2022-09-14 |
Small Pharma Ltd |
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
|
|
CN115867533B
(zh)
|
2020-06-30 |
2024-07-23 |
加拿大瑞安神经科学公司 |
色胺前药
|
|
WO2022018709A1
(en)
|
2020-07-21 |
2022-01-27 |
Ai Pharmaceuticals Jamaica Limited |
Compositions and methods for treatment of psychoses and psychotic disorders
|
|
US11000534B1
(en)
|
2020-10-08 |
2021-05-11 |
Lennham Pharmaceuticals, Inc. |
Deuterated derivatives of psilocybin and uses thereof
|